CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (12)

Name (Synonyms) Correlation
drug752 Nitazoxanide Wiki 0.71
drug262 Chloroquine Wiki 0.46
drug802 Other drugs Wiki 0.41
drug1148 Therapeutic Anticoagulation Wiki 0.41
drug1343 modification of the planned therapeutic management Wiki 0.41
drug749 Niclosamide Wiki 0.29
drug527 Hydroxychloroquine Sulfate 200 MG [Plaquenil] Wiki 0.24
drug431 Favipiravir Wiki 0.13
drug647 Lopinavir/ritonavir Wiki 0.12
drug108 Azithromycin Wiki 0.08
drug850 Placebo Wiki 0.07
drug505 Hydroxychloroquine Wiki 0.04

Correlated MeSH Terms (13)

Name (Synonyms) Correlation
D001943 Breast Neoplasms NIH 0.41
D010051 Ovarian Neoplasms NIH 0.41
D014846 Vulvar Neoplasms NIH 0.41
D002583 Uterine Cervical Neoplasms NIH 0.41
D014594 Uterine Neoplasms NIH 0.41
D014625 Vaginal Neoplasms NIH 0.41
D020141 Hemostatic Disorders NIH 0.20
D001778 Blood Coagulation Disorders NIH 0.20
D009369 Neoplasms, NIH 0.12
D018352 Coronavirus Infections NIH 0.06
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D003141 Communicable Diseases NIH 0.04

Correlated HPO Terms (8)

Name (Synonyms) Correlation
HP:0100615 Ovarian neoplasm HPO 0.41
HP:0010784 Uterine neoplasm HPO 0.41
HP:0100650 Vaginal neoplasm HPO 0.41
HP:0030416 Vulvar neoplasm HPO 0.41
HP:0030079 Cervix cancer HPO 0.41
HP:0003002 Breast carcinoma HPO 0.41
HP:0001928 Abnormality of coagulation HPO 0.20
HP:0002664 Neoplasm HPO 0.12

There are 6 clinical trials

Clinical Trials

1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment

Efficacy of Ivermectin and Nitazoxanide in COVID-19 treatment

NCT04351347 COVID Drug: Chloroquine Drug: Nitazoxanide Drug: Ivermectin

Primary Outcomes

Description: Number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

3 To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study

At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.

NCT04373824 COVID Drug: Ivermectin

Primary Outcomes

Description: Test for virus at 1, 3 & 5 days from beginning of trial drug started for the patient in the hospital

Measure: effect of Ivermectin on eradication of virus.

Time: 3 months

4 Novel Treatment Regimens in Treatment of COVID-19

Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: the number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

5 Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission

SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.

NCT04390022 Covid-19 Coronavirus Infection SARS-CoV-2 Infection Drug: Ivermectin Drug: Placebo
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment

Measure: Proportion of patients with a positive SARS-CoV-2 PCR

Time: 7 days post-treatment

Secondary Outcomes

Description: Change from baseline quantitative and semi-quantitative PCR in nasopharyngeal swab

Measure: Mean viral load

Time: Baseline and on days 4, 7, 14 and 21

Description: Proportion of patients with fever and cough at days 4, 7, 14 and 21 as well as proportion of patients progressing to severe disease or death during the trial

Measure: Fever and cough progression

Time: Up to and including day 21

Description: Proportion of participants with positive IgG at day 21

Measure: Seroconversion at day 21

Time: Up to and including day 21

Description: Proportion of drug-related adverse events

Measure: Proportion of drug-related adverse events

Time: 7 days post treatment

Description: Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay

Measure: Levels of IgG, IgM and IgA

Time: Up to and including day 28

Description: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry

Measure: Frequency of innate immune cells

Time: Up to and including day 7

Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry

Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells

Time: Up to and including day 7

Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher)

Measure: Results from cytokine Human Magnetic 30-Plex Panel

Time: Up to and including day 28

6 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial

Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.

NCT04391127 COVID-19 Drug: Hydroxychloroquine Drug: Ivermectin Drug: Placebo
MeSH:Infe Infection

Primary Outcomes

Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge

Measure: Mean days of hospital stay

Time: Three months

Description: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.

Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead

Time: Three months

Description: Daily delta of oxygenation index during the hospitalization

Measure: Mean of oxygenation index delta

Time: Three months

Secondary Outcomes

Description: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.

Measure: Mean time to viral PCR negativization

Time: One month

No related HPO nodes (Using clinical trials)